Urinary Infections Clinical Trial
Official title:
Study of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections.
The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections
Status | Completed |
Enrollment | 180 |
Est. completion date | July 2007 |
Est. primary completion date | July 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 16 Years and older |
Eligibility |
Inclusion Criteria: - Hospitalized patients over 16 years of age with complicated urinary infection produced by bacteria that are suspected to be susceptible to treatment with Piperacillin-tazobactam. Exclusion Criteria: - Patients known, or thought to be hypersensitivity to beta-lactams - Patients with an uncomplicated urinary tract infection |
Observational Model: Case-Only, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Wyeth is now a wholly owned subsidiary of Pfizer |
Spain,
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00560924 -
Preventive Effect of Treatment With Estradiol Vaginal Tablets on Recurrent Urinary Tract Infections in Post-menopausal Women
|
Phase 3 | |
Recruiting |
NCT02658903 -
Prevention of Catheter Associated Lower Urinary Infections Using the Oxys Indwelling Catheter
|
Phase 1 |